Here, we reported experiments of gain-of-function obtained by over-expressing oncogenic KRASG12V in glioblastoma, studying the cisplatin resistance in relationship with single-point-mutations HVR K-RAS post-translational modification. Here, KRAS is linked to glioblastoma.